Devices descending from K180936
5 later devices reach ETEST Telavancin (TLA) (0.002-32 ug/mL) through their predicates, nearest generation first.
| Generation | Number | Device | Applicant | Decided | Own descendants | Recalls |
|---|---|---|---|---|---|---|
| +1 | K200512 | ETEST Plazomicin (PLZ) (0.016-256 µg/mL) | Biomérieux SA | 2020 | 0 | — |
| +1 | K192738 | ETEST Delafloxacin (DFX) (0.002-32 µg/mL) | Biomerieux S.A. | 2019 | 0 | — |
| +1 | K192050 | ETEST Eravacycline (ERV) (0.002 – 32 µg/mL) | Biomerieux S.A. | 2019 | 2 | 1 |
| +2 | K210757 | ETEST Fosfomycin (FO) (0.032-512 µg/mL) | Biomerieux S.A. | 2021 | 1 | — |
| +3 | K260447 | ETEST Gepotidacin (GEP) (0.016-256 µg/mL) | bioMérieux SA | 2026 | 0 | — |